In Vitro Evaluation of Cenderitide-eluting Stent I -an Antirestenosis and Proendothelization Approach

Overview

Journal J Pharm Sci

Publisher Elsevier

Specialties Pharmacology
Pharmacy

Date 2014 Sep 17

PMID 25223419

Citations 3

Authors

Xu Wen Ng

Yingying Huang

Kerh Lin Liu

Soon Ghim Lim

Horng Haur Chen

John C Burnett Jr

Yin Chiang Freddy Boey

Subbu S Venkatraman

Affiliations

Soon will be listed here.

Abstract

Despite the success that drug-eluting stents (DESs) have achieved for minimizing in-stent restenosis (ISR), the antirestenotic agents used in DES have been implicated in delayed endothelial healing and impairment of endothelial functions. Cenderitide (CD-NP) is a novel antiproliferation chimeric peptide of semiendothelial origin; thus, this paper aims to demonstrate the selectivity aspect of this new peptide via in vitro evaluation on key players in ISR-smooth muscle cells (SMCs) and endothelial cells. The microbicinchoninic acid protein assay was used to investigate the CD-NP release from films and stents. Cenderitide-containing films blended with poly(ethylene glycol) and its copolymer exhibited higher release kinetics compared with neat poly(ε-caprolactone) (PCL) formulation. Cenderitide-eluting stents (CES) was produced by coating bare metallic stents with CD-NP entrapped PCL using an ultrasonic spray coater. The investigation of CD-NP on in vitro cells revealed that CD-NP inhibits human coronary smooth muscle cells (HCaSMCs) proliferation but exhibits no effects on human umbilical vein endothelial cells (HUVECs) proliferation. Moreover, CD-NP released up to 7 days displayed inhibitory effects on SMCs proliferation. The CES produced in this work shows that the released CD-NP inhibits HCaSMCs proliferation but did not hamper HUVECs proliferation in vitro, suggesting that it has potential to reduce ISR without retarding the endothelialization healing in vivo.

Citing Articles

The utilization of c-type natriuretic peptide levels on experimental muscle and kidney ischemia/reperfusion model.

Cakirkose O, Kesici U, Kesici S, Sipahi M, Tokgoz V, Guvendi G Malawi Med J. 2025; 36(3):220-226.

PMID: 40018399 PMC: 11862850. DOI: 10.4314/mmj.v36i3.8.

Translation in cardiovascular stents and occluders: From biostable to fully degradable.

Huang Y, Wong Y, Ng H, Boey F, Venkatraman S Bioeng Transl Med. 2018; 2(2):156-169.

PMID: 29313029 PMC: 5675095. DOI: 10.1002/btm2.10066.

Novel Biological Therapies Targeting Heart Failure: Myocardial Rejuvenation.

Favreau-Lessard A, Ryzhov S, Sawyer D Heart Fail Clin. 2016; 12(3):461-71.

PMID: 27371521 PMC: 5214584. DOI: 10.1016/j.hfc.2016.03.008.

In vivo Evaluation of Cenderitide-Eluting Stent (CES) II.

Huang Y, Ng X, Lim S, Chen H, Burnett Jr J, Boey Y Ann Biomed Eng. 2015; 44(2):432-41.

PMID: 26178873 PMC: 4715776. DOI: 10.1007/s10439-015-1389-1.

References

Furuya M, Yoshida M, Hayashi Y, Ohnuma N, Minamino N, Kangawa K . C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1991; 177(3):927-31. DOI: 10.1016/0006-291x(91)90627-j. View

Huang Y, Venkatraman S, Boey F, Lahti E, Umashankar P, Mohanty M . In vitro and in vivo performance of a dual drug-eluting stent (DDES). Biomaterials. 2010; 31(15):4382-91. DOI: 10.1016/j.biomaterials.2010.01.147. View

Drachman D, Edelman E, Seifert P, Groothuis A, Bornstein D, Kamath K . Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol. 2000; 36(7):2325-32. DOI: 10.1016/s0735-1097(00)01020-2. View

Diwan M, Park T . Pegylation enhances protein stability during encapsulation in PLGA microspheres. J Control Release. 2001; 73(2-3):233-44. DOI: 10.1016/s0168-3659(01)00292-9. View

Scotland R, Ahluwalia A, Hobbs A . C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther. 2005; 105(2):85-93. DOI: 10.1016/j.pharmthera.2004.08.011. View

Siepmann F, Hoffmann A, Leclercq B, Carlin B, Siepmann J . How to adjust desired drug release patterns from ethylcellulose-coated dosage forms. J Control Release. 2007; 119(2):182-9. DOI: 10.1016/j.jconrel.2007.02.003. View

Liu K, Widjaja E, Huang Y, Ng X, Loo S, Boey F . A new insight for an old system: protein-PEG colocalization in relation to protein release from PCL/PEG blends. Mol Pharm. 2011; 8(6):2173-82. DOI: 10.1021/mp200513b. View

Woodard G, Rosado J . Natriuretic peptides in vascular physiology and pathology. Int Rev Cell Mol Biol. 2008; 268:59-93. DOI: 10.1016/S1937-6448(08)00803-4. View

Degertekin M, Serruys P, Foley D, Tanabe K, Regar E, Vos J . Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation. 2002; 106(13):1610-3. DOI: 10.1161/01.cir.0000034447.02535.d5. View

10.

Furuya M, Tawaragi Y, Minamitake Y, Kitajima Y, Fuchimura K, Tanaka S . Structural requirements of C-type natriuretic peptide for elevation of cyclic GMP in cultured vascular smooth muscle cells. Biochem Biophys Res Commun. 1992; 183(3):964-9. DOI: 10.1016/s0006-291x(05)80284-0. View

11.

Hasdai D, Behar S, Wallentin L, Danchin N, Gitt A, Boersma E . A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J. 2002; 23(15):1190-201. DOI: 10.1053/euhj.2002.3193. View

12.

Lang N, Newby D . Emerging thrombotic effects of drug eluting stents. Arterioscler Thromb Vasc Biol. 2007; 27(2):261-2. DOI: 10.1161/01.ATV.0000255308.41576.ae. View

13.

Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A . Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther. 2004; 102(3):223-41. DOI: 10.1016/j.pharmthera.2004.04.004. View

14.

Barr C, Rhodes P, Struthers A . C-type natriuretic peptide. Peptides. 1996; 17(7):1243-51. DOI: 10.1016/s0196-9781(96)00110-6. View

15.

Lisy O, Huntley B, McCormick D, Kurlansky P, Burnett Jr J . Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008; 52(1):60-8. PMC: 2575424. DOI: 10.1016/j.jacc.2008.02.077. View

16.

van de Weert M, Hennink W, Jiskoot W . Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 2001; 17(10):1159-67. DOI: 10.1023/a:1026498209874. View

17.

Schwartz R, Chronos N, Virmani R . Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004; 44(7):1373-85. DOI: 10.1016/j.jacc.2004.04.060. View

18.

Johnson P, Skornia S, Stabenfeldt S, Willits R . Maintaining bioactivity of NGF for controlled release from PLGA using PEG. J Biomed Mater Res A. 2007; 86(2):420-7. DOI: 10.1002/jbm.a.31635. View

19.

Kobialka M, Gorczyca W . Particulate guanylyl cyclases: multiple mechanisms of activation. Acta Biochim Pol. 2001; 47(3):517-28. View

20.

Stone G, Moses J, Ellis S, Schofer J, Dawkins K, Morice M . Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007; 356(10):998-1008. DOI: 10.1056/NEJMoa067193. View